1. Opening HookRemember when Ayurveda was just about neem and haldi? Well, Jeena Sikho’s “Acharya” just turned it into a ₹190 crore quarterly juggernaut. While FMCG giants fight for shelf space, Acharya Manish ji is selling wellness like it’s IPL merchandise — loud, fast, and with divine conviction. From “Om Arogyam Astu” to “EBITDA 48%,” this quarter had everything — chants, charts, and chaos. Grab your herbal tea — the real drama comes when investors start asking about beds, margins, and Chandan Diagnostics. 😏
2. At a Glance
- Revenue up 66%– From ₹114 crore to ₹190 crore; Ayurveda finally hit steroids (figuratively).
- EBITDA ₹92 crore, up 129%– Margins fatter than a festive ladoo box.
- PAT ₹59 crore, up 121%– Acharya ji’s blessings seem tax-exempt.
- Occupancy 57%– Beds are half-full, optimism is overflowing.
- 2,802 beds vs 1,600 YoY– Expansion faster than Baba Ramdev’s TV ads.
- Stock?– Traders already chanting “Om multibagger namah.”
3. Management’s Key Commentary
“We’ve achieved 66% growth year-on-year and 9% quarter-over-quarter.”(Translation: Even Excel was surprised.)
“EBITDA margin at 48% shows our operational efficiency.”(Translation: We’re making profits faster than hospitals can get fire NOCs.)
“We added 582 beds in six months — promised 2,800 for the year, already done.”(Translation: Overachievement is our favorite yoga pose.)
“Tied up with Chandan Diagnostics; 34 centers active already.”(Translation: Free blood tests, full diagnostics, and infinite footfalls — win-win, or at least that’s the mantra.)
“Our focus is to reach 7,000–10,000 beds in 3–5 years.”(Translation: We plan hospitals like startups plan Series C.)
“We’re launching 15–20 OTC products including BP, sugar, and depression tablets.”(Translation: FMCG
meets Ayurveda — Dabur should probably start stretching.)
“Salesforce helped us fix confused patients.”(Translation: CRM meets CRM — Customer RelationshipMantra.) 🧘
4. Numbers Decoded
| Metric | Q2 FY26 | Q2 FY25 | YoY Growth | Comment |
|---|---|---|---|---|
| Revenue (₹ Cr) | 190 | 114 | +66% | Herbal demand soaring |
| EBITDA (₹ Cr) | 92 | 40 | +129% | Margin magic potion |
| EBITDA Margin (%) | 48 | 35 | +13 bps | Efficiency meets energy |
| PAT (₹ Cr) | 59 | 27 | +121% | Pure detox profits |
| Beds (Nos) | 2802 | 1600 | +75% | “Hospital construction as therapy” |
| Occupancy (%) | 57 | 55 | — | Still room for more yogis |
| OPD Volume (Nos) | 1.40 L | 1.24 L | +13% | Clinics buzzing |
| IPD Volume (Nos) | 9,614 | 8,616 | +12% | Beds filling up slowly |
Analysis:Margins look divine, but sustainability remains mortal. Growth is herbal; scaling is allopathic.
5. Analyst Questions
- On Pet Shuddhi Kit:“Sales rising across UP, Bihar, and Delhi.” (Dogs getting detoxed before humans.)
- On Chandan tie-up:“Their 40 lakh customers now ours.” (Perfect definition of shared karma.)
- On Bed Targets:“Slowing addition, focusing on occupancy.” (Finally, some breathing exercise.)
- On Margins:“Healthy at 20–25%, anything
